Allogene Therapeutics (ALLO) Accumulated Depreciation (2018 - 2019)

Allogene Therapeutics (ALLO) reported Accumulated Depreciation of $1.6 million for Q1 2019, up 51.91% sequentially from $1.0 million in Q4 2018.

Allogene Therapeutics (ALLO) Accumulated Depreciation (2018 - 2019) Analysis & Trends

Allogene Therapeutics (ALLO) has 2 years of Accumulated Depreciation data on file, last reported at $1.6 million in Q1 2019.

For the quarter ending Q1 2019, Accumulated Depreciation changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2019 stood at $1.6 million (changed N/A YoY), and the FY2018 full-year result was $1.0 million, changed N/A from the prior year.
Accumulated Depreciation rose to $1.6 million in Q1 2019, from $1.0 million in the prior quarter.
In the past five years, Accumulated Depreciation ranged from a high of $1.6 million in Q1 2019 to a low of $1.0 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Allogene Therapeutics	437.33 Mn	437.33 Mn	-

Download Data

Date	Value
Mar 31, 2019	1.59 Mn
Dec 31, 2018	1.05 Mn